In Japan, regulatory success is built on consultation

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has spent the past decade trying to make the country a more attractive place to develop and launch innovative drugs and biologics. The most visible signal is the Sakigake designation program, which offers priority consultation and a faster review target for eligible products, plus policy incentives that can support earlier market entry.

At the same time, sponsors are trying to modernize clinical evidence packages. Patient-reported outcomes (PROs) are now routinely included in global trials, and interest is rising in digital biomarkers and other digitally derived measures that could serve as endpoints. Japan is part of that shift, but the agency’s expectations tend to be shaped by structured consultation, conservative endpoint claims, and an emphasis on predictable, decision-grade evidence.

For foreign sponsors, the practical challenge is not that Japan uses different science. It is that the PMDA’s review process rewards early alignment and carefully bounded claims, which can be harder to deliver when endpoints have a subjective aspect, as in the case of PROs, or when they are technically complex, as in the case of digital measures.